Special Guest · 8:00–8:15 AM PT
?
Special guest
Charla Triplett - ULP deal
Pitches · 8:15–9:30 AM PT
Restec Solutions
Currie Crookston, CEO · ccrookston@restecs.com
RESTEC has developed the first point-of-care automated surface sterilization system specifically designed for common patient care items that are not compatible with current sterilization processes.
Round
$1MM Undecided @ $25MM
Closed
$500K
FDA milestone
Passed sterilization testing, have FDA agreement on predicates, with supporting testing in process
FDA timeline
Submit the end of Q1, end of Q2 into Q3 clearance
Other groups in round
Friends and family
DD package
no
Traction: Siemens commitment to purchase 1,000 units post launch. Commitments from 5 health systems to purchase after clearance. Validation testing with Baxter underway
What they're looking for: We have KOLs, but would appreciate broadening our group
Nephrogen
Demetri Maxim, CEO · dmaxim@nephrogenbiotech.com
Nephrogen uses AI and high-throughput experimental screening to identify safer, more efficient gene delivery vehicles to enable curative gene therapies; business model is to license discovered delivery vehicles to pharma.
Round
$3M Post-money SAFE @ $20M valuation cap (post-money SAFE)
Closed
$2.1M closed; $350K committed; $500K remaining
FDA milestone
N/A (licensing delivery vehicles; revenue not dependent on FDA milestones)
DD package
Diligence memo from lead investors can be forwarded
Traction: 7 paid pilots/research sponsorships with pharma (Novartis, Merck KGaA, BMS, Otsuka, Chiesi, Alnylam, Bayer); $625K total deal value; $375K trailing 12-month revenue.
What they're looking for: Intro to a large animal facility (non-human primates or pigs), specifically Texas BioMedical Research Institute / Southwest National Primate Center; introductions to scientific/BD staff at additional pharma companies.